ASH Clinical News ACN_4.10_FULL ISSUE web | Page 49
ACTUALLY BE
COULD THE
BPDCN?
HEMATOLOGIC
CANCER
YOU JUST
What the CD 123 diagnostic marker
can tell you*
DIAGNOSED …
CD123
CD4
CD56
Knowing can be as simple as CD 123
CD 123
is a rapidly emerging therapeutic target
in hematologic cancer. 1
BPDCN may present as other
hematologic cancers, including 1,3-5 :
CD 123,
as part of the signature marker triad in
combination with CD 4 and CD 56, is a key marker
in identifying the aggressive hematologic cancer,
blastic plasmacytoid dendritic cell neoplasm
(BPDCN)—an often underrecognized and
misdiagnosed disease. 1-4 *
• AML • ALL
• Leukemia cutis • MDS
• Cutaneous lymphoma • CMML
• NHL
CONSIDER CD 123 IN INITIAL HEMATOLOGIC DIAGNOSTIC PANELS. 1
Visit BPDCNinfo.com
AML = acute myeloid leukemia; NHL = non-Hodgkin’s lymphoma; ALL = acute lymphoblastic leukemia; MDS = myelodysplastic syndrome;
CMML = chronic myelomonocytic leukemia.
*BPDCN diagnosis can include other markers, such as CD 4, CD 56, TCL1, and CD 303 (BDCA2). 6
References: 1. Pagano L, Valentini CG, Grammatico S, Pulsoni A. Br J Haematol. 2016;174(2):188-202. 2. Facchetti F, Cigognetti M, Fisogni S, Rossi G, Lonardi S,
Vermi W. Mod Pathol. 2016;29(2):98-111. 3. Riaz W, Zhang L, Horna P, Sokol L. Cancer Control. 2014;21(4):279-289. 4. Pemmaraju N. Curr Hematol Malig Rep.
2017;12(6):510-512. 5. Laribi K, Denizon N, Besançon A, et al. Biol Blood Marrow Transplant. 2016;22(8):1357-1367. 6. Reichard KK. Surg Pathol Clin.
2013;6(4):743-765.
Copyright 2018 - Stemline Therapeutics, Inc.
All rights reserved.
07/2018
2018042